Supervised Online Resistance Training vs Unsupervised Self-administered Resistance Training for Elders

NCT ID: NCT05885165

Last Updated: 2023-07-07

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-20
• Study Completion Date: 2023-11-15

Brief Summary

The primary goal of this project is to investigate whether online supervised team-based exercise training is superior for increasing functional strength in elders compared to prescribed self-administered exercise training. Secondarily, the project aims to investigate whether adherence to online supervised team-based exercise training is greater compared to prescribed self-administered training, and if online supervised team-based exercise training can increase quality of life. Finally, this project will generate more knowledge on elderly individuals' approaches and responses to physical exercise through online services. The participants will undergo a 12-week intervention where they will be performing prescribed physical exercise for 5 hours bi-weekly and complete a 3-day dietary registration three times during the study. Participants will be randomized (2:1 ratio) to two groups and will: i) undergo supervised training in groups on an online live meeting platform by trained personnel, or ii) receive prescribed exercises through an online exercise platform but their training will be self-administered and unsupervised.

Conditions

Healthy Aging

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: SINGLE

Study Groups

Supervised team-based exercise

In this arm, participants will receive guided training by an instructor in teams of 10 on the online platform Zoom.

Group Type: EXPERIMENTAL

Supervised team-based exercise

Intervention Type: BEHAVIORAL

The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.

Unsupervised exercise

In this arm, participants will perform the training individually with the exercises provided on the platform Exorlive, which is a one-way communication platform. However, the first two weeks (5 training sessions) will be conducted in teams of 10 participants with the presence of an instructor who will introduce, demonstrate, and supervise correct form and technique and ensure understanding of the exercise concept.

Group Type: ACTIVE_COMPARATOR

Unsupervised exercise

Intervention Type: BEHAVIORAL

The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.

Interventions

Supervised team-based exercise

The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.

Intervention Type: BEHAVIORAL

Unsupervised exercise

The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Age ≥ 65 years.
• Danish reading and listening proficiency.
• Participant is in possession of either a computer, tablet, or smartphone in order to participate in Zoom meetings (supervised team-based group) or training programs via Exorlive (unsupervised group).
• The participant is able to walk independently and without external aids.

Exclusion Criteria

• BMI > 35 kg/m2.
• Participation in other intervention studies or intention to do so, which are likely to affect the present study.
• Known diseases which may affect energy expenditure and/or satiation/satiety/food intake i.e. inflammatory bowel disease, thyroid diseases.
• Current diagnosis of eating disorder (e.g. restrained eating, disinhibition, emotional eating).
• Psychiatric disorders i.e. schizophrenia, bipolar disease or depression with hospitalization within the last 6 months.
• History or diagnosis of cardiovascular disease including current angina; myocardial infarction; coronary revascularization procedures; stroke (either ischemic or hemorrhagic, including transient ischemic attacks); symptomatic peripheral artery disease that required surgery or was diagnosed with vascular imaging techniques; ventricular arrhythmia; uncontrolled atrial fibrillation; congestive heart failure (New York Heart Association Class II to IV); myocardiopathy; and history of aortic aneurysm ≥5.5 cm in diameter or aortic aneurysm surgery within the past six months, as diagnosed by a medical doctor.
• Systolic blood pressure above 160 mmHg and/or diastolic blood pressure above 100 mmHg whether on or off treatment for hypertension. If being treated, stable treatment (i.e. no change in treatment, either dose, type of medication or other changes) within the last three months is required.
• History or diagnosis of chronic kidney disease.
• History or diagnosis of liver disease.
• Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption.
• Systemic treatment with glucocorticoids inhalations and creams etc. is allowed
• Cancer: active malignant cancer or history of malignancy within the last five years (with exception of local basal and squamous cell skin cancer).
• Previous bariatric surgery or intention to undergo bariatric surgery within the next 12 months.
• History of extensive small or large bowel resection.
• Known endocrine origin of obesity (except for treated hypothyroidism).
• Current use of prescription medication or use within the previous month that has the potential of affecting body weight such as systemic corticosteroids (excluding inhaled and topical steroids), psychoactive medication, epileptic medication, or weight loss medications (either prescription, over the counter or herbal). Low dose antidepressants are allowed if they, in the judgment of the investigator, do not affect body weight or participation in the study protocol. Levothyroxine for treatment of hypothyroidism is allowed if the subject has been on a stable dose for at least three months.
• Concurrent therapy with immunosuppressive drugs or cytotoxic agents.

• Minimum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Studnitz Consulting

UNKNOWN

Sponsor Role: collaborator

Aktiv Hele Livet v. Rasmus Stagsted

UNKNOWN

Sponsor Role: collaborator

Aktiv Hele Livet v. Manuel Thomasen

UNKNOWN

Sponsor Role: collaborator

Moustgaard Consulting

UNKNOWN

Sponsor Role: collaborator

University of Copenhagen

OTHER

Sponsor Role: lead

Responsible Party

Faidon Magkos

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Faidon Magkos, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Copenhagen

Locations

University of Copenhagen

Copenhagen, , Denmark

Countries

Denmark

Other Identifiers

514-0396/23-5000

Identifier Type: -

Identifier Source: org_study_id